To: Board of Supervisors
From: Anna Roth, Health Services Director
Report Title: Amendment #76-752-2 with Roche Diagnostics Corporation
☒Recommendation of the County Administrator ☐ Recommendation of Board Committee
RECOMMENDATIONS:
APPROVE and AUTHORIZE the Health Services Director, or designee, to execute on behalf of the County Contract Amendment #76-752-2 with Roche Diagnostics Corporation, a corporation, to amend Contract #76-752 (as amended by Amendment #76-752-1), effective upon execution of agreement, for additional test kits, reagents and supplies for the Cobas laboratory analyzer used for patient specimen testing at Contra Costa Regional Medical Center (CCRMC) , with no change in the payment limit of $2,577,330 or termination date of December 31, 2032.
FISCAL IMPACT:
Approval of this Amendment will not result in an increase to the original payment limit which is funded 100% by Hospital Enterprise Fund I.
BACKGROUND:
This Contract meets the needs of CCRMC and its health centers, allowing the Roche Cobas 5800 System, aiding in the automation, integration, consolidation, and standardization of high-volume and molecular testing such as COVID-19 and influenza and allows in-house testing. The Roche Cobas 5800 System includes ancillary test equipment, reagents, and supplies for CCRMC clinical laboratories and pathology to process, test, and analyze patient specimens. CCRMC has been using Roche products since 2010.
On December 21, 2021, the Board of Supervisors approved Contract #76-752 with Roche Diagnostics Corporation, in the amount not to exceed $1,530,425, for the purchase of the Roche Cobas 6800 fully automated patient specimen testing system for the period August 11, 2021 through August 10, 2026.
On February 27, 2024, the Board of Supervisors approved Amendment Agreement #76-752-1 to increase the payment limit by $1,046,875 to a new total of $2,577,300 and extend the term through December 31, 2032 and allow CCRMC to trade in the Cobas 6800 and upgrade its current testing platform to the Cobas 5800 analyzer, which includes specifications required by the Centers for Medicare & Medicaid Services to meet Clinical Laboratory Improvement Amendments and Federal Drug Administration accreditation requirements. The Cobas 5800 offers a compact, fully automated molecular system that aids in high demands and streamlines the process to a single platform, including preventative maintenance, real-time support, and on-site service.
Approval of Contract Amendment #76-752-2 allows for additional test kits, reagents and supplies needed for patient testing, through December 31, 2032.
CONSEQUENCE OF NEGATIVE ACTION:
If this amendment is not approved, the health services department will not have the necessary test kits, reagents and supplies needed for specimen testing at CCRMC.